Duchenne Muscular Dystrophy Clinical Trial Updates 2024 | FDA Approvals, Therapies in Focus | Vyondys 53 (Golodirsen), Emflaza, Exondys 51, Translarna, Amondys 45, Viltepso, PF-06939926, Vamorolone

Duchenne Muscular Dystrophy Clinical Trial Updates 2024 | FDA Approvals, Therapies in Focus | Vyondys 53 (Golodirsen), Emflaza, Exondys 51, Translarna, Amondys 45, Viltepso, PF-06939926, Vamorolone
Duchenne Muscular Dystrophy Pipeline Insight
Several major pharma and biotech companies such as Sarepta Therapeutics, PTC Therapeutics, Nippon Shinyaku, Pfizer, Santhera Pharmaceuticals/ReveraGen BioPharma, Taiho Pharmaceutical, FibroGen, Capricor, Daiichi Sankyo, Italfarmaco, Antisense Therapeutics, Solid Biosciences, among others, are actively working in the Duchenne Muscular Dystrophy Market.

As per DelveInsight’s assessment, globally, about 75+ key pharma and biotech companies are working on 75+ pipeline drugs in the Duchenne Muscular Dystrophy (DMD) therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Duchenne Muscular Dystrophy (DMD) Pipeline Insight, 2024” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Duchenne Muscular Dystrophy Market. 

The Duchenne Muscular Dystrophy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Duchenne Muscular Dystrophy Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for the treatment of Duchenne Muscular Dystrophy and the aggregate therapies developed by major pharma companies.
  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.
  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Duchenne Muscular Dystrophy market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc. 

DelveInsight’s Report covers around 75+ products under different phases of clinical development like –

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) 
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

Route of Administration – The Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROA, such as –

  • Oral
  • Intravenous
  • Subcutaneous

Molecule Type – Products have been categorized under various Molecule types, such as

  • Small molecule
  • Cell Therapy
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

Duchenne Muscular Dystrophy Emerging Therapies – Mechanisms of Action (MOA) Types

  • Dipeptidyl peptidase I inhibitors
  • Peroxisome proliferator-activated receptor delta modulators
  • Cell replacements
  • Dystrophin expression stimulants
  • Connective tissue growth factor inhibitors
  • Dystrophin replacements
  • Immunostimulants
  • Gene modulators
  • Dystrophin expression modulators

Learn How the Ongoing Clinical & Commercial Activities will Affect the Duchenne Muscular Dystrophy Therapeutic Segment @ https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-pipeline-insight

Duchenne Muscular Dystrophy Therapeutics Landscape

There are approx. 75+ key companies developing therapies for Duchenne Muscular Dystrophy. Currently, Roche is leading the therapeutics market with its Duchenne Muscular Dystrophy drug candidates in the most advanced stage of clinical development among all the major players in the segment.

Leading Companies in the Duchenne Muscular Dystrophy Therapeutics Market Include:

  • Santhera Pharmaceuticals
  • Sarepta Therapeutics
  • Italfarmaco
  • Wave Life Sciences Ltd
  • FibroGen
  • Edgewise Therapeutics
  • Fordadistrogene movaparvovec
  • Daiichi Sankyo
  • Sarepta Therapeutics, Inc.
  • ENCell
  • Taiho Pharmaceutical
  • Solid Biosciences
  • Capricor
  • Nippon Shinyaku
  • Hansa Biopharma
  • And Many Others

Duchenne Muscular Dystrophy Drugs Covered in the Report Include:

  • Vamorolone: Santhera
  • Givinostat: Italfarmaco
  • Pamrevlumab: Fibrogen
  • WVE N531: WaVe lifeSciences
  • CRISPR/Cas9 gene editing therapy: Vertex Pharmaceuticals
  • MA-0211: Mitobridge
  • BLS-M22: Bioleaders Corporation
  • CAP 1002: Capricor
  • DS-5141: Daiichi Sankyo
  • TAS-205: Taiho Pharmaceutical
  • And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @ https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-pipeline-insight

Table of Content

1. Report Introduction

2. Executive Summary

3. Duchenne Muscular Dystrophy Current Treatment Patterns

4. Duchenne Muscular Dystrophy – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Duchenne Muscular Dystrophy Late Stage Products (Phase-III)

7. Duchenne Muscular Dystrophy Mid-Stage Products (Phase-II)

8. Duchenne Muscular Dystrophy Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Duchenne Muscular Dystrophy Discontinued Products

13. Duchenne Muscular Dystrophy Product Profiles

14. Key Companies in the Duchenne Muscular Dystrophy Market

15. Key Products in the Duchenne Muscular Dystrophy Therapeutics Segment

16. Dormant and Discontinued Products

17. Duchenne Muscular Dystrophy Unmet Needs

18. Duchenne Muscular Dystrophy Future Perspectives

19. Duchenne Muscular Dystrophy Analyst Review  

20. Appendix

21. Report Methodology

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/